PR Newswire - A Potential First-In-Class Drug: CDE Approved Sing...
NANJING, China, April 30, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independentl...
Read More


ภาษาไทย
English